You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Home Monitoring of Metabolic Disorders
SBC: SEQUITUR HEALTH CORP Topic: NICHDPROJECT SUMMARY This proposal is submitted in direct response to NOT-HD-22-009 Notice of Special Interest (NOSI): Innovative Technologies to Improve Assessments, Interventions, and Outcomes for Individuals with Intellectual and Developmental Disabilities [IDD] (R43/R44). Persons of all ages with certain metabolic disorders are at-risk for metabolic crises when a certain metabolite accumulates, whi ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies
SBC: EXAVIR THERAPEUTICS INC. Topic: NIAIDPROJECT SUMMARY While there are now successful treatment regimens and prevention strategies for people living with HIV/AIDS, the HIV pandemic remains a public health crisis in the United States and worldwide, with nearly 40,000 new infections each year in the US alone. To prevent the spread of HIV in vulnerable populations, the US Preventive Services Task Force has recommended HIV pre-exposure pro ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Dodecafluoropentane emulsion (DDFPe), NanO2™ as Cerebroprotectant in Ischemic Stroke
SBC: NUVOX PHARMA, L.L.C. Topic: NINDSABSTRACT / PROJECT SUMMARY Stroke affects more than 795,000 patients per year in the US and kills approximately 40,000. Long-term medical care expense for stroke in the US, costs over $34B per year. Large vessel occlusion (LVO) stroke accounts for almost 40% of ischemic strokes but causes 95% of mortality and 62% of long-term dependence. Mechanical thrombectomy (MT), or a combination of MT and tPA ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Cutaneous Phosphorylated Alpha-Synuclein for Detection of Prodromal Synucleinopathies
SBC: CND LIFE SCIENCES, INC. Topic: 105PROJECT SUMMARY A group of devastating diseases, collectively termed synucleinopathies, affect over 2 million people in the U.S., carry significant morbidity, high mortality and enormous associated health care costs. Synucleinopathies are characterized by the abnormal deposition of a misfolded protein, phosphorylated α−synuclein (P-SYN), within the central and peripheral nervous systems. Synucl ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Preclinical evaluation of an otoprotectant TT002
SBC: TING THERAPEUTICS LLC Topic: NIDCDProject Summary Ting Therapeutics LLC is a pharmaceutical company developing drugs to prevent and treat hearing loss. Cisplatin is one of the most widely used drugs to treat cancers. However, cisplatin therapy causes hearing loss in 40-60% of the patients. To date, no drugs have been approved by the Food and Drug Administration for protection from cisplatin-induced hearing loss (CIHL). Most candid ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Enabling Toxoplasma gondii Kinome Directed Drug Discovery
SBC: LUCEOME BIOTECHNOLOGIES, L.L.C. Topic: NIAIDProject Summary Toxoplasma gondii (T.gondii), the causative agent for toxoplasmosis, invades host cells through ingestion of uncooked infected meat or contaminated water. T.gondii infects 30% of the world’s population and the current cost of the disease in US itself is estimated to be $3B and rising. Current treatment regimen is effective only against acute infection and has severe side effects. ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
CDK2 inhibitors for protecting hearing loss
SBC: TING THERAPEUTICS LLC Topic: NIDCDCDK2 inhibitors for protecting hearing loss Ting Therapeutics LLC is a pharmaceutical company developing drugs to prevent and treat hearing loss. Cisplatin is one of the most widely used drugs to treat cancers. However cisplatin anticancer therapy causes high frequency hearing loss in 40-60% of the patients. To date, no drugs have been approved by the Food and Drug Administration for protection fr ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Whole Blood Point of Care Metabolic Measurement
SBC: SEQUITUR HEALTH CORP Topic: NICHDProject Summary This SBIR Phase II project will translate Phase I technical innovations in sensor materials and a prototype device into a fully functional point of care technology for whole blood biomarker monitoring. It will culminate in a complete draft of a 510(k) clearance application to the U.S. Food and Drug Administration (FDA). Currently, no commercial FDA cleared point of care device is a ...
SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Development of SP-A Derived Peptidomimetics for the Treatment of Asthma- Phase II
SBC: RaeSedo, LLC Topic: NHLBICurrent treatments for asthma, while reducing exacerbations in a subset of patients by focusing on airway inflammation, do not eliminate them. Asthma exacerbations are a significant cause of morbidity and mortality in asthma as they can lead to airway injury, lung function decline and death. Exacerbations in more severe asthmatics are of particular concern, as health care costs and lost productivi ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health
SBC: NEUTHERAPEUTICS, LLC Topic: NIAPROJECT SUMMARY/ABSTRACT Women are at greater life-time risk for Alzheimer’s disease (AD). One potential factor contributing to greater life-time risk of AD is the midlife menopausal endocrine aging transition when multiple AD risk conditions can emerge and which are consistent with prodromal / preclinical features of the disease. While estrogen or hormone therapy administered when menopausal wo ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health